Temperature-controllable photo-thermal treatment hydrogel as well as preparation method and application thereof

By using nanoprecipitation method to load metal chelating agents in photothermal materials, the problem of inaccurate temperature control in photothermal treatment is solved, and temperature-controllable tumor treatment is achieved, which avoids damage to surrounding tissues and improves Accuracy and safety of treatment.

CN118902987APending Publication Date: 2024-11-08TAN KAH KEE INNOVATION LAB +1

Patent Information

Application Number
CN202411287829.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-13
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The existing photothermal treatment materials are not accurate enough in temperature control, which causes too high temperature during the treatment to damage the surrounding tissues. There are already metal chelating agents that can destroy the polyphenol-metal coordination bonds, causing the material to lose its photothermal properties. , temperature-controllable tumor treatment cannot be achieved.

Method used

Polyvinylpyrrolidone, polyphenol compounds, trivalent iron compounds, surfactants, phase change materials and metal chelating agents are used to load metal chelating agents into phase change materials through nanoprecipitation method to form temperature-controlled nanoparticles and put them in Loading into photothermal materials, the metal chelating agent is released when the phase transition temperature is reached, cutting off the coordination effect of polyphenol compounds and trivalent iron, and preventing the temperature from continuing to rise.

Benefits of technology

It realizes temperature-controllable photothermal therapy, has excellent photothermal performance, can cut off coordination at specific temperatures, prevent temperature increase, and avoid damage to surrounding tissues, providing accurate treatment for tumors.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118902987A_ABST
    Figure CN118902987A_ABST
Patent Text Reader

Abstract

The invention relates to preparation and application of temperature-controllable photo-thermal therapy hydrogel. The temperature-controllable photo-thermal therapy hydrogel comprises polyvinylpyrrolidone (PVP), a polyphenol compound, a ferric iron compound, a surfactant, a phase change material and a metal chelating agent. The preparation process of the temperature-controllable photo-thermal treatment hydrogel comprises the following steps: performing nano precipitation on a surfactant, a phase change material and a metal chelating agent, performing centrifugal ultrafiltration to obtain temperature-controlled nano particles, then adding the temperature-controlled nano particles into a photo-thermal material prepared from polyvinylpyrrolidone (PVP), a polyphenol compound and a ferric iron compound, and preparing the temperature-controllable photo-thermal treatment hydrogel. The temperature-controllable photo-thermal treatment hydrogel is obtained. The temperature-controllable photo-thermal treatment hydrogel is simple in preparation process and easy to operate, and has excellent photo-thermal performance; when the phase change temperature of the phase change material is reached, the metal chelating agent is released, the coordination effect of the polyphenol compound and ferric iron is cut off, the system temperature is prevented from continuing to rise, and temperature-controllable tumor photothermal therapy is achieved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of new biomedical materials, and in particular relates to the preparation and application of a temperature-controllable photothermal therapy hydrogel. Background Art

[0002] For decades, finding a treatment for cancer has been a focus of attention. Currently, available treatment options include surgery, chemotherapy, photothermal therapy, radiotherapy, etc. Among them, photothermal therapy, as a non-invasive treatment, has the advantages of less trauma, repeatable treatment, and obvious effect, and has received widespread attention in cancer treatment (see Chee Wee Ng, Jingchao Li, and Kanyi Pu. Recent Progresses in Phototherapy-Synergized Cancer Immunotherapy. Adv. Funct. Mater. 2018, 28, 1804688). Although photothermal therapy is an effective method for treating cancer, the treatment temperature is difficult to accurately control during the treatment process, and excessively high temperatures can cause damage to surrounding tissues. It is necessary to develop photothermal materials that can achieve reversal of photothermal effects at a specific temperature.

[0003] Materials prepared based on the coordination of polyphenolic compounds with ferric ions have been widely used in photothermal therapy due to their good photothermal properties. And this coordination can be destroyed by metal chelators. Metal chelators approved by the U.S. Food and Drug Administration (FDA) for clinical iron overload treatment have a stronger interaction with ferric ions, which can compete with polyphenol-metal coordination compounds, destroy the coordination bonds between polyphenols and metals, and make the material lose photothermal properties (see Yanbing Wang, Zhuo Wang, Caina Xu, Huayu Tiana, and Xuesi Chen. A disassembling strategy overcomes the EPR effect and renal clearance dilemma of the multifunctional theranostic nanoparticles for cancer therapy. Biomaterials 2019, 197, 284-293).

[0004] On the other hand, as a new type of controlled release thermal response material, phase change material can undergo solid-liquid phase change at a specific temperature, and has been used as a thermal response carrier for drug loading and responsive release. The encapsulated payload is released only when the phase change material undergoes a solid-liquid phase change (see Chunlei Zhu, Da Huo, Qiaoshan Chen, Jiajia Xue, Song Shen, and Younan Xia. A Eutectic Mixture of Natural Fatty Acids Can Serve as the Gating Material for Near-Infrared-Triggered Drug Release. Adv. Mater. 2017, 1703702). Different phase change materials and their combination ratios have different phase change temperatures, and the phase change response temperature can be customized according to actual needs.

[0005] In view of this, the present invention provides a preparation and application of a temperature-controllable photothermal therapy hydrogel, including polyvinyl pyrrolidone (PVP), a polyphenol compound, a trivalent iron compound, a surfactant, a phase change material and a metal chelator. The metal chelator is loaded into the phase change material by a nanoprecipitation method to obtain temperature-controlled nanoparticles. The nanoparticles are loaded into a photothermal material prepared from polyvinyl pyrrolidone (PVP), a polyphenol compound and a trivalent iron compound to obtain a temperature-controllable photothermal therapy hydrogel. The temperature-controllable photothermal therapy hydrogel has a simple preparation process, is easy to operate, and has excellent photothermal performance; when the phase change temperature of the phase change material is reached, the metal chelator is released, the coordination effect between the polyphenol compound and the trivalent iron is cut off, and the system temperature is prevented from continuing to rise, thereby realizing temperature-controllable tumor photothermal therapy, which fills the gap in this field. Summary of the invention

[0006] The purpose of the present invention is to develop a temperature-controllable photothermal therapy hydrogel. The temperature-controllable photothermal therapy hydrogel has a simple preparation process, is easy to operate, and has excellent photothermal performance; when the phase change temperature of the phase change material is reached, the metal chelating agent is released to cut off the coordination effect between the polyphenol compound and the trivalent iron, preventing the system temperature from continuing to rise, achieving temperature control, and realizing temperature-controllable tumor photothermal therapy.

[0007] A first aspect of the present invention provides a temperature-controllable photothermal therapy hydrogel, comprising: polyvinyl pyrrolidone, a polyphenol compound, a trivalent iron compound, a surfactant, a phase change material and a metal chelator.

[0008] According to the temperature-controllable photothermal therapy hydrogel of the first aspect, the weight average molecular weight of the polyvinyl pyrrolidone is 8000 to 1300000 Da.

[0009] According to the temperature-controllable photothermal therapy hydrogel of the first aspect, the polyphenol compound is selected from one or more of flavonoids, isoflavones, flavonols, dihydroflavonoids, dihydroflavonols, biflavonoids, gallic acid, protocatechuic acid, p-hydroxybenzoic acid, resveratrol, lignans, chlorogenic acid, anthocyanidins, quercetin, curcumin, cocoa polyphenols, tartrate, rutin, tannic acid, catechin, epicatechin, gallol catechin, epigallocatechin, and epigallocatechin gallate;

[0010] The trivalent iron compound is selected from one or more of ferric nitrate, ferric chloride, ferric sulfate, etc.;

[0011] The surfactant is selected from one or more of distearoylphosphatidylethanolamine-polyethylene glycol 2000, methoxy polyethylene glycol-dimyristoyl-racemic-glycerol, and methoxy polyethylene glycol ditetradecyl acetamide; and / or

[0012] The metal chelator is selected from one or more of deferoxamine, deferiprone, deferasirox, ethylenediaminetetraacetic acid, and disodium ethylenediaminetetraacetic acid.

[0013] According to the temperature-controllable photothermal therapy hydrogel of the first aspect, the phase change material is selected from fatty acids and / or fatty alcohols;

[0014] Preferably, the fatty acid is selected from one or more of capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, and cannabinoid acid; and / or

[0015] Preferably, the fatty alcohol is selected from one or more of 1-dodecanol, 1-tridecanol, 1-tetradecanol, 1-pentadecanol, hexadecanol, and 1-octadecanol.

[0016] According to the temperature-controllable photothermal therapy hydrogel of the first aspect, the mass ratio of the phase change material, the metal chelator and the surfactant is (0.01-5):(0.01-0.5):1;

[0017] The molar ratio of the polyphenol compound, the trivalent iron compound and the polyvinyl pyrrolidone is (1-60):(1-100):1; and / or

[0018] The molar ratio of the trivalent iron compound to the metal chelating agent is 1:(1-50).

[0019] The second aspect of the present invention provides a method for preparing the temperature-controllable photothermal therapy hydrogel of the first aspect, comprising:

[0020] The surfactant, phase change material and metal chelator are nanoprecipitated to obtain temperature-controlled nanoparticles; the temperature-controlled nanoparticles are mixed with polyvinyl pyrrolidone, polyphenol compounds and trivalent iron compounds to obtain a temperature-controllable photothermal therapy hydrogel.

[0021] According to the method of the second aspect, the method comprises the following steps:

[0022] (1) under vigorous stirring, a phase change material and a metal chelating agent mixed solution dissolved in an organic reagent are added dropwise to a preheated surfactant aqueous solution, stirred at room temperature, and centrifuged and ultrafiltered to obtain temperature-controlled nanoparticles;

[0023] (2) The temperature-controlled nanoparticles prepared in step (1), the aqueous solution of polyphenol compounds and the aqueous solution of polyvinyl pyrrolidone are mixed to obtain a mixed solution, and then the aqueous solution of trivalent iron compound is added dropwise to the mixed solution and stirred to obtain a temperature-controllable photothermal therapy hydrogel.

[0024] According to the method of the second aspect, in step (1), the organic solvent is selected from one or more of methanol, N,N-dimethylformamide, acetone, tetrahydrofuran, and dichloromethane;

[0025] The preheating temperature of the surfactant aqueous solution is 20 to 80°C;

[0026] The room temperature stirring time is 0.1 to 5 hours;

[0027] The centrifugal speed is 3000-10000 rpm;

[0028] The centrifugation time is 5 to 30 minutes; and / or

[0029] The ultrafiltration cut-off is 1000-100000Da.

[0030] According to the method of the second aspect, in step (2), the stirring time after the trivalent iron compound is added dropwise is 0.5 to 5 hours.

[0031] The third aspect of the present invention provides use of the temperature-controllable photothermal therapy hydrogel of the first aspect or the temperature-controllable photothermal therapy hydrogel prepared according to the method of the second aspect in the preparation of drugs for photothermal therapy.

[0032] The temperature-controllable photothermal therapy hydrogel of the present invention has but is not limited to the following beneficial effects:

[0033] The temperature-controllable photothermal therapy hydrogel prepared by the present invention has good photothermal performance and can realize photothermal therapy for tumors. The photothermal therapy system can release the loaded metal chelator when the system reaches the phase change temperature of the phase change material, cut off the coordination effect between the polyphenol compound and trivalent iron, prevent the system temperature from continuing to rise, and realize temperature-controllable tumor photothermal therapy, which has certain universality. BRIEF DESCRIPTION OF THE DRAWINGS

[0034] Figure 1 The temperature rise curves of the photothermal therapy hydrogels prepared in Example 59 and Comparative Example 1 are shown.

[0035] Figure 2 A comparison diagram of Example 59 before and after illumination is shown. DETAILED DESCRIPTION

[0036] The present application is further described in detail below through the accompanying drawings and embodiments. Through these descriptions, the characteristics and advantages of the present application will become clearer and more specific.

[0037] The word "exemplary" is used exclusively herein to mean "serving as an example, embodiment, or illustration." Any embodiment described herein as "exemplary" is not necessarily to be construed as preferred or advantageous over other embodiments. Although various aspects of the embodiments are shown in the drawings, the drawings are not necessarily drawn to scale unless otherwise noted.

[0038] In addition, the technical features involved in different embodiments of the present application described below can be combined with each other as long as they do not conflict with each other.

[0039] The invention provides a temperature-controllable photothermal therapy hydrogel, comprising: polyvinyl pyrrolidone, a polyphenol compound, a trivalent iron compound, a surfactant, a phase change material and a metal chelating agent.

[0040] The temperature-controllable photothermal therapy hydrogel of the present invention loads the metal chelator in the phase change material by nanoprecipitation method to obtain temperature-controlled nanoparticles; the nanoparticles are loaded into the photothermal material prepared by polyvinyl pyrrolidone (PVP), polyphenol compounds and trivalent iron compounds to obtain the temperature-controllable photothermal therapy hydrogel. The temperature-controllable photothermal therapy hydrogel has excellent photothermal performance; when the phase change temperature of the phase change material is reached, the metal chelator is released, the coordination effect between the polyphenol compounds and the trivalent iron is cut off, the system temperature is prevented from continuing to rise, and temperature-controllable tumor photothermal therapy is achieved.

[0041] The temperature-controlled nanoparticles of the present invention are further prepared into hydrogel preparations. During tumor treatment, if nanoparticles are administered intravenously, it is necessary to wait for the drug to be enriched at the tumor site, and the drug loading amount must not be too high. If the drug loading amount is too high, it will cause drug poisoning reactions and increase the side effects of the drug. On the basis of temperature-controlled photothermal therapy, hydrogels can also provide stable drug delivery points, with convenient drug delivery and accurate metering. Photothermal therapy can be performed immediately after injection without enrichment. Since it does not enter the blood circulation, there is no need to consider the impact of the loading amount.

[0042] In one embodiment, the weight average molecular weight of the polyvinyl pyrrolidone is 8000 to 1300000 Da.

[0043] In the temperature-controllable photothermal therapy hydrogel of the present invention, if the molecular weight of polyvinyl pyrrolidone is too low, the hydrogel will be unstable and unable to form a stable drug delivery point, while if the molecular weight is too high, the viscosity will be too high, affecting the drug delivery effect.

[0044] In one embodiment, the polyphenolic compound is selected from one or more of flavonoids, isoflavones, flavonols, dihydroflavonoids, dihydroflavonols, biflavonoids, gallic acid, protocatechuic acid, p-hydroxybenzoic acid, resveratrol, lignans, chlorogenic acid, anthocyanidins, quercetin, curcumin, cocoa polyphenols, tartrate, rutin, tannic acid, catechin, epicatechin, gallic acid catechin, epigallocatechin, and epigallocatechin gallate;

[0045] The trivalent iron compound is selected from one or more of ferric nitrate, ferric chloride, ferric sulfate, etc.;

[0046] The surfactant is selected from one or more of distearoylphosphatidylethanolamine-polyethylene glycol 2000, methoxy polyethylene glycol-dimyristoyl-racemic-glycerol, and methoxy polyethylene glycol ditetradecyl acetamide; and / or

[0047] The metal chelator is selected from one or more of deferoxamine, deferiprone, deferasirox, ethylenediaminetetraacetic acid, and disodium ethylenediaminetetraacetic acid.

[0048] In one embodiment, the phase change material is selected from fatty acids and / or fatty alcohols;

[0049] Preferably, the fatty acid is selected from one or more of capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, and cannabinoid acid; and / or

[0050] Preferably, the fatty alcohol is selected from one or more of 1-dodecanol, 1-tridecanol, 1-tetradecanol, 1-pentadecanol, hexadecanol, and 1-octadecanol.

[0051] In a specific embodiment, the phase change material is a blend of lauric acid and stearic acid; preferably, in the blend of lauric acid and stearic acid, the mass ratio of lauric acid to stearic acid is (1-10):1, such as 2:1, 3:1, 4:1, 5:1, 6:1, 8:1; in a preferred embodiment, in the blend of lauric acid and stearic acid, the mass ratio of lauric acid to stearic acid is 4:1.

[0052] In one embodiment, the mass ratio of the phase change material, the metal chelating agent and the surfactant is (0.01-5):(0.01-0.5):1;

[0053] The molar ratio of the polyphenol compound, the trivalent iron compound and the polyvinyl pyrrolidone is (1-60):(1-100):1; and / or

[0054] The molar ratio of the trivalent iron compound to the metal chelating agent is 1:(1-50).

[0055] The present invention also provides a method for preparing the temperature-controllable photothermal therapy hydrogel, comprising:

[0056] The surfactant, phase change material and metal chelator are nanoprecipitated to obtain temperature-controlled nanoparticles; the temperature-controlled nanoparticles are mixed with polyvinyl pyrrolidone, polyphenol compounds and trivalent iron compounds to obtain a temperature-controllable photothermal therapy hydrogel.

[0057] In one embodiment, the method comprises the following steps:

[0058] (1) under vigorous stirring, a phase change material and a metal chelating agent mixed solution dissolved in an organic reagent are added dropwise to a preheated surfactant aqueous solution, stirred at room temperature, and centrifuged and ultrafiltered to obtain temperature-controlled nanoparticles;

[0059] (2) The temperature-controlled nanoparticles prepared in step (1), the aqueous solution of polyphenol compounds and the aqueous solution of polyvinyl pyrrolidone are mixed to obtain a mixed solution, and then the aqueous solution of trivalent iron compound is added dropwise to the mixed solution and stirred to obtain a temperature-controllable photothermal therapy hydrogel.

[0060] In one embodiment, in step (1), the organic solvent is selected from one or more of methanol, N,N-dimethylformamide, acetone, tetrahydrofuran, and dichloromethane;

[0061] The preheating temperature of the surfactant aqueous solution is 20 to 80°C;

[0062] The room temperature stirring time is 0.1 to 5 hours;

[0063] The centrifugal speed is 3000-10000 rpm;

[0064] The centrifugation time is 5 to 30 minutes; and / or

[0065] The ultrafiltration cut-off is 1000-100000Da.

[0066] In one embodiment, in step (2), the stirring time after the ferric iron compound is added dropwise is 0.5 to 5 hours.

[0067] The present invention also provides the use of the temperature-controllable photothermal therapy hydrogel in the preparation of drugs for photothermal therapy.

[0068] The present invention provides a temperature-controllable photothermal therapy hydrogel prepared by the preparation method described in the above technical solution and its application in the field of biomedicine. The present invention emphasizes photothermal therapy, but is not limited to the field of photothermal therapy. The application field can be defined according to the type and function of the selected polyphenol compound and the phase change temperature of the phase change material. Disease therapeutic agents, disease diagnostic agents or disease preventive agents such as chemotherapeutic drugs can be added to the temperature-controllable photothermal therapy hydrogel of the present invention to achieve combined therapy.

[0069] The temperature-controllable photothermal therapy hydrogel prepared by the present invention has good photothermal performance and can realize photothermal therapy for tumors. The photothermal therapy system can release the loaded metal chelator when the system reaches the phase change temperature of the phase change material, cut off the coordination effect between the polyphenol compound and trivalent iron, prevent the system temperature from continuing to rise, and realize temperature-controllable tumor photothermal therapy, which has certain universality.

[0070] In order to further illustrate the present invention, the technical solution of the present invention is described in detail below in conjunction with embodiments.

[0071] All raw materials of the present invention have no particular restrictions on their sources, and can be purchased from the market or prepared according to conventional methods known to those skilled in the art. In the examples, the methods used are all conventional methods unless otherwise specified.

[0072] In the following embodiments, when the phase change material is a lauric acid-stearic acid blend, the mass ratio of lauric acid to stearic acid is 4:1.

[0073] Preparation Example 1: Preparation of Temperature-Controlled Nanoparticles

[0074] Under vigorous stirring, a phase change material dissolved in an organic reagent and a mixed solution of a metal chelator labeled with Cy5 are added dropwise to a pre-heated surfactant aqueous solution, stirred at room temperature, and finally centrifuged and ultrafiltered to obtain temperature-controlled nanoparticles. The mass ratio of the phase change material, the metal chelator and the surfactant is preferably (0.01-5):(0.01-0.5):1. Specific examples are shown in Table 1 below:

[0075] Table 1

[0076]

[0077]

[0078]

[0079]

[0080]

[0081] Preparation Example 2: Particle Size Test of Temperature-Controlled Nanoparticles

[0082] Subsequently, a potentiometric particle size analyzer was used to measure the particle size of the temperature-controlled nanoparticles (Examples 1-54) prepared in Preparation Example 1. The results are shown in Table 2 below:

[0083] Table 2

[0084]

[0085]

[0086]

[0087] The results show that the particle size of the nanoparticles prepared according to the above materials and proportions is stable at 80 to 170 nm.

[0088] Preparation Example 3: Drug loading and drug loading efficiency

[0089] The metal chelator labeled with Cy5 fluorescence was loaded into the phase change material. After ultrafiltration and enrichment, it was resuspended in water and detected by an ELISA instrument. The drug loading amount and drug loading efficiency of the metal chelator in the nanoparticles prepared in Examples 1 to 54 were calculated by the following formula, and the results are shown in Table 3 below.

[0090] Drug loading (wt%) = (actual drug loading / total drug amount) × 100%

[0091] Drug loading efficiency (wt%) = (actual drug loading / original dosage) × 100%

[0092] The actual drug loading is the amount of Cy5 fluorescently labeled metal chelator in the prepared nanoparticles, the total drug amount is the amount of the prepared nanoparticles, and the original dosage is the dosage for preparing the Cy5 fluorescently labeled metal chelator.

[0093] Table 3

[0094]

[0095]

[0096]

[0097] The results showed that the Cy5 fluorescently labeled metal chelator was successfully loaded into the phase change material by nanoprecipitation, demonstrating the successful preparation of temperature-controlled nanoparticles.

[0098] Preparation Example 4: Preparation of temperature-controllable photothermal therapy hydrogel

[0099] The temperature-controlled nanoparticles, the aqueous solution of the polyphenol compound and the aqueous solution of the polyvinyl pyrrolidone are mixed, and then the aqueous solution of the trivalent iron compound is added dropwise to the mixed solution and stirred to obtain a temperature-controllable photothermal therapy hydrogel. The weight-average molecular weight of polyvinyl pyrrolidone (PVP) is preferably 8000-1300000 Da, the molar ratio of the polyphenol compound, the trivalent iron compound and the polyvinyl pyrrolidone (PVP) is preferably (1-60): (1-100): 1, and the final concentration molar ratio of the trivalent iron compound to the metal chelator is preferably 1: (1-50). In this preparation example, the temperature-controlled nanoparticles of Examples 55-63, Examples 82-90, and Examples 109-117 are prepared by the method of Example 5, the temperature-controlled nanoparticles of Examples 64-72, Examples 91-99, and Examples 118-126 are prepared by the method of Example 41, and the temperature-controlled nanoparticles of Examples 73-81, Examples 100-108, and Examples 127-135 are prepared by the method of Example 23. In the following examples, the final concentration of trivalent iron ions in the prepared temperature-controllable photothermal therapy hydrogel is 2.2 mg / mL. Specific examples are shown in Table 4 below:

[0100] Table 4

[0101]

[0102]

[0103]

[0104]

[0105]

[0106] Test Example 1: Photothermal Performance Evaluation

[0107] The temperature-controllable photothermal hydrogels of the same volume and different compositions were heated by 808 nm laser at a power density of 0.8 W / cm 2 The irradiation was performed for 10 minutes. The temperature was recorded every 10 seconds using an infrared thermal imaging camera. The results of the highest heating temperatures in different embodiments are shown in Table 5 below. Taking Embodiment 59 as an example, the heating curve is shown in Figure 1 As shown, Figure 1 The comparison of Example 59 before and after illumination without adding Figure 2 shown.

[0108] Table 5

[0109]

[0110]

[0111]

[0112]

[0113] The results showed that the temperature-controllable photothermal therapy hydrogel was successfully prepared, and the maximum elevated temperature was related to the phase change temperature of the phase change material.

[0114] Test Example 2: Cytotoxicity Test

[0115] In the present invention, 4T1 cell line is selected, and the cell culture method is not particularly limited, and can be based on methods well known to those skilled in the art. In the present invention, the cells are preferably cultured in an incubator containing 10% fetal bovine serum, and the culture conditions are preferably continuous culture in an incubator with a volume fraction of 5% carbon dioxide, and the culture temperature is preferably 37°C.

[0116] The 4T1 cell line was used to evaluate the photothermal performance at the cellular level. The cells were plated at 1×10 4 The cells co-cultured with different materials were irradiated with 808 nm laser, and the laser density was preferably 0.5-1.5 W / cm 2 , more preferably 0.7 to 1.3 W / cm 2 The laser density used in this test example is 0.8, and the irradiation time is preferably 3 to 20 minutes, more preferably 5 to 15 minutes. The laser irradiation time used in this test example is 10 minutes. After the irradiation is completed, the culture is continued for 24 hours. Then, wash 3 times with PBS and add new culture medium, add 20 μL of thiazolyl blue solution (5 mg / mL) to each well, and continue to culture for 4 hours. The liquid in the 96-well plate is aspirated and dimethyl sulfoxide is added, and the absorbance value of each well at 490nm is detected by an enzyme reader. The cell survival rate is calculated by the following formula. The results are shown in Table 6.

[0117] Cell survival rate (%) = (absorbance of sample well / absorbance of blank well) × 100%

[0118] Table 6

[0119]

[0120]

[0121]

[0122]

[0123]

[0124] The results show that the temperature-controllable photothermal therapy hydrogel has no obvious cytotoxicity without laser irradiation; under laser irradiation, the cytotoxicity of the temperature-controllable photothermal therapy hydrogel is related to the phase change temperature of the phase change material.

[0125] Experimental Example 3: In vivo photothermal anti-tumor study

[0126] Animal model: In the present invention, the 4T1 tumor model was used in the experiment, and BALB / c mice were used for the photoacoustic experiment. The density of subcutaneous inoculation was 1×10 6 The 4T1 cells of the cells were cultured, and when the tumor grew to a certain size, imaging and treatment experiments at the animal level were started.

[0127] In vivo photothermal anti-tumor study: When the tumor volume grows to 60-150mm 3 When the temperature-controlled photothermal hydrogel is injected into the subcutaneous area around the tumor tissue through a 1 mL syringe, the laser is then irradiated with an 808 nm laser, and the laser density is preferably 0.5 to 1.5 W / cm 2 , more preferably 0.7 to 1.3 W / cm 2 The laser density used in this test example is 0.8W / cm 2 The irradiation time is preferably 3 to 20 minutes, more preferably 5 to 15 minutes. The laser irradiation time used in this test example is 10 minutes. After the irradiation, the weight and tumor volume (or relative tumor volume) of the mice were tracked for 4 weeks. The tumor volume (or relative tumor volume) can be calculated by the following formula:

[0128] Tumor volume (mm 3 ) = (length of tumor × width of tumor × width of tumor) / 2

[0129] Relative tumor volume = tumor volume / initial tumor volume × 100%

[0130] A comparative experiment is provided, wherein:

[0131] Comparative Example 1: Photothermal therapy hydrogel without phase change material

[0132] The preparation method is as follows: an aqueous solution of a polyphenol compound is mixed with an aqueous solution of polyvinyl pyrrolidone, and then a trivalent iron compound aqueous solution is added dropwise to the mixed solution and stirred to obtain a photothermal therapy hydrogel without a phase change material. The weight average molecular weight of polyvinyl pyrrolidone (PVP) is preferably 8000 to 1300000 Da, more preferably 24000 to 50000 Da, and the molecular weight of polyvinyl pyrrolidone (PVP) used in this comparative example is 40000 Da. The polyphenol compound used in this comparative example is tannic acid. The molar ratio of polyphenol compounds, trivalent iron compounds and polyvinyl pyrrolidone (PVP) is preferably (1 to 60): (1 to 100): 1, and the molar ratio of polyphenol compounds, trivalent iron compounds and polyvinyl pyrrolidone (PVP) used in this comparative example is 30:50:1.

[0133] The photothermal performance of the photothermal hydrogel without phase change material prepared in Comparative Example 1 was tested by the method of Experimental Example 1. The temperature rise curve is as follows: Figure 1 shown.

[0134] Comparative Example 2: Temperature-controllable photothermal therapy nanoparticles

[0135] The preparation method is as follows: temperature-controlled nanoparticles and an aqueous solution of a polyphenol compound are mixed, and then an aqueous solution of a trivalent iron compound is added dropwise to the mixed solution and stirred to obtain temperature-controllable photothermal therapy nanoparticles. The temperature-controlled nanoparticles of this comparative example are prepared by the method of Example 41. The polyphenol compound used in this comparative example is tannic acid. The molar ratio of the polyphenol compound to the trivalent iron compound used in this comparative example is 3:5. The final concentration ratio of the trivalent iron compound to the metal chelator used in this comparative example is 1:25.

[0136] Temperature-controllable photothermal therapy nanoparticles containing 0.25 mg / mL trivalent iron ions were prepared according to the above method.

[0137] Tumor-bearing mice were prepared according to the method described in Experimental Example 3, and the temperature-controllable photothermal therapy nanoparticles containing 0.25 mg / mL trivalent iron ions prepared in Comparative Example 2 were injected into the tumor-bearing mice through the tail vein. When the nanoparticles were most enriched in the tumor, 808 nm laser was used for irradiation, and the changes in the tumor volume of the mice were recorded.

[0138] The temperature-controllable photothermal therapy nanoparticles containing 0.25 mg / mL trivalent iron ions prepared in Comparative Example 2 were injected into tumor-bearing mice peritumorally according to the method described in Experimental Example 3, and irradiated with 808 nm laser, and the changes in the tumor volume of the mice were recorded.

[0139] Comparative Example 3:

[0140] Temperature-controllable photothermal therapy nanoparticles containing 2.5 mg / mL of trivalent iron ions were prepared according to the method of Comparative Example 2.

[0141] The temperature-controllable photothermal therapy nanoparticles containing 2.5 mg / mL trivalent iron ions prepared in Comparative Example 3 were injected into tumor-bearing mice peritumorally according to the method described in Experimental Example 3, and irradiated with 808 nm laser, and the changes in the tumor volume of the mice were recorded.

[0142] The results are shown in Table 7.

[0143] Table 7

[0144]

[0145]

[0146] The results show that the temperature-controllable photothermal therapy hydrogel has no obvious anti-tumor effect when there is no laser irradiation; under laser irradiation, the tumor inhibition effect of the temperature-controllable photothermal therapy hydrogel is related to the phase change temperature of the phase change material. In comparative example 1, when there is no phase change material and laser irradiation, the system temperature will continue to rise. Although the tumor cells can be completely killed in the end, the excessive temperature will cause damage to the surrounding tissues due to the uncontrollable temperature. Comparative Examples 2 and 3 provide a method for preparing temperature-controllable photothermal therapy nanoparticles without PVP. In the process of tumor treatment, if nanoparticles are administered intravenously, it is necessary to wait for the drug to be enriched in the tumor position, and the drug loading should not be too high. If the drug loading is too high, it will cause drug poisoning reaction, and it will aggravate the side effects of the drug, and in severe cases, it will cause the death of mice; while the hydrogel can provide a stable drug delivery point, convenient drug delivery and accurate metering, and photothermal therapy can be performed immediately after injection, without enrichment, and without considering the effect of the load on the mouse; while the use of nanoparticles for direct tumor injection will result in drug dispersion, so that the drug cannot stay near the tumor, and the tumor inhibition effect is poor. The low-concentration nanoparticles of Comparative Example 2 were used to perform intravenous injection and para-tumor injection on tumor-bearing mice, respectively. It can be seen that the tumors injected intravenously are relatively larger in volume and the therapeutic effect is worse, indicating that there is a certain amount of drug loss in the process of drug enrichment for intravenous administration. The low-concentration nanoparticles of Comparative Example 2 and the high-concentration nanoparticles of Comparative Example 3 were respectively injected para-tumorally. It can be seen that when the drug loading of the nanoparticles is increased, the inhibition of the tumor is more obvious and the therapeutic effect is better. In the temperature-controllable photothermal therapy hydrogel of Example 104, the temperature-controllable nanoparticles prepared in Example 41 were also used, and the final concentration of trivalent iron was 2.2 mg / mL, which is equivalent to the therapeutic effect of the nanoparticles containing 2.5 mg / mL trivalent iron ions in Comparative Example 3, indicating that the hydrogel is more conducive to the aggregation of drugs. Further, when other drugs such as chemotherapeutic drugs are contained in the drug delivery system, the hydrogel system has a better drug aggregation effect than the nanoparticle system.

[0147] The present application has been described above in conjunction with preferred embodiments, but these embodiments are only exemplary and serve only as an illustration. On this basis, various replacements and improvements may be made to the present application, all of which fall within the scope of protection of the present application.

Claims

1. A temperature-controllable photothermal therapy hydrogel, comprising: Polyvinyl pyrrolidone, polyphenol compounds, trivalent iron compounds, surfactants, phase change materials and metal chelating agents.

2. The temperature-controllable photothermal therapy hydrogel according to claim 1, characterized in that: The weight average molecular weight of the polyvinyl pyrrolidone is 8000-1300000 Da.

3. The temperature-controllable photothermal therapy hydrogel according to claim 1, characterized in that: The polyphenolic compound is selected from one or more of flavonoids, isoflavones, flavonols, dihydroflavonoids, dihydroflavonols, biflavonoids, gallic acid, protocatechuic acid, p-hydroxybenzoic acid, resveratrol, lignans, chlorogenic acid, anthocyanidins, quercetin, curcumin, cocoa polyphenols, tartrazine, rutin, tannic acid, catechin, epicatechin, gallic acid catechin, epigallocatechin, and epigallocatechin gallate; The trivalent iron compound is selected from one or more of ferric nitrate, ferric chloride, ferric sulfate, etc.; The surfactant is selected from one or more of distearoylphosphatidylethanolamine-polyethylene glycol 2000, methoxy polyethylene glycol-dimyristoyl-racemic-glycerol, and methoxy polyethylene glycol ditetradecyl acetamide; and / or The metal chelator is selected from one or more of deferoxamine, deferiprone, deferasirox, ethylenediaminetetraacetic acid, and disodium ethylenediaminetetraacetic acid.

4. The temperature-controllable photothermal therapy hydrogel according to claim 1, characterized in that: The phase change material is selected from fatty acids and / or fatty alcohols; Preferably, the fatty acid is selected from one or more of capric acid, lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, and cannabinoid acid; and / or Preferably, the fatty alcohol is selected from one or more of 1-dodecanol, 1-tridecanol, 1-tetradecanol, 1-pentadecanol, hexadecanol, and 1-octadecanol.

5. The temperature-controllable photothermal therapy hydrogel according to any one of claims 1 to 4, characterized in that: The mass ratio of the phase change material, the metal chelating agent and the surfactant is (0.01-5):(0.01-0.5):1; The molar ratio of the polyphenol compound, the trivalent iron compound and the polyvinyl pyrrolidone is (1-60):(1-100):1; and / or The molar ratio of the trivalent iron compound to the metal chelating agent is 1:(1-50).

6. The method for preparing the temperature-controllable photothermal therapy hydrogel according to any one of claims 1 to 5, comprising: Nanoprecipitating a surfactant, a phase change material, and a metal chelating agent to obtain temperature-controlled nanoparticles; The temperature-controlled nanoparticles are mixed with polyvinyl pyrrolidone, polyphenol compounds and trivalent iron compounds to obtain a temperature-controllable photothermal therapy hydrogel.

7. The method according to claim 6, characterized in that The method comprises the following steps: (1) under vigorous stirring, a phase change material and a metal chelating agent mixed solution dissolved in an organic reagent are added dropwise to a preheated surfactant aqueous solution, stirred at room temperature, and centrifuged and ultrafiltered to obtain temperature-controlled nanoparticles; (2) The temperature-controlled nanoparticles prepared in step (1), the aqueous solution of polyphenol compounds and the aqueous solution of polyvinyl pyrrolidone are mixed to obtain a mixed solution, and then the aqueous solution of trivalent iron compound is added dropwise to the mixed solution and stirred to obtain a temperature-controllable photothermal therapy hydrogel.

8. The method according to claim 7, characterized in that In step (1), the organic solvent is selected from one or more of methanol, N,N-dimethylformamide, acetone, tetrahydrofuran, and dichloromethane; The preheating temperature of the surfactant aqueous solution is 20 to 80°C; The room temperature stirring time is 0.1 to 5 hours; The centrifugal speed is 3000-10000 rpm; The centrifugation time is 5 to 30 minutes; and / or The ultrafiltration cut-off is 1000-100000Da.

9. The method according to claim 7, characterized in that: In step (2), the stirring time after the trivalent iron compound is added dropwise is 0.5 to 5 hours.

10. Use of the temperature-controllable photothermal therapy hydrogel according to any one of claims 1 to 5 or the temperature-controllable photothermal therapy hydrogel prepared by the method according to any one of claims 6 to 9 in the preparation of drugs for photothermal therapy.

Citation Information

Patent Citations

  • Liposome nanoparticles as well as preparation method and application thereof

    CN115501337A

  • Method for preparing injectable polyphenol-macromolecule adhesive hydrogel

    CN115651218A

  • Thermal therapy composition, pharmaceutical composition and preparation method and application thereof

    CN115944729A

Cited By

  • Gelatin-based nano composite hydrogel as well as preparation method and application thereof

    CN121319410A